Since tumors with KRAS mutations were characterized by reduced infiltration and inactivation of CD8+ T cells in the immune microenvironment, the efficacy of KRAS inhibitors relied on the presence and activation of CD8+ T cells for effective tumor elimination.[60, 61] Therefore, targeting the enhancement of CD8+ T cell function was an important combined therapeutic strategy. The gene discussed is KRAS; the disease is neoplasm.